LIVZON PHARMA's application for marketing authorization of Lecanemab injection has been accepted
LIVZON PHARMA (01513.HK) announced that its holding subsidiary, LIVZON Monoclonal Antibody, received a notification from the National Medical Products Administration. The application for the domestic production drug registration and marketing authorization of Lakanqita Monoclonal Antibody Injection, jointly developed with Beijing Xinkanghe, has been accepted. The intended indication is for adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments